New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 27, 2014
09:01 EDTPCYCPharmacyclics downgraded to Sector Perform from Outperform at RBC Capital
RBC Capital downgraded Pharmacyclics to Sector Perform and reduced its price target to $95 from $110 to reflect upcoming headwinds from ABBVIE and Gilead upcoming filings, slowing new scripts data, Phase III RESONATE data at ASCO might not have the buzz expected and lack of near-term catalysts.
News For PCYC From The Last 14 Days
Check below for free stories on PCYC the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 25, 2014
16:02 EDTPCYCPharmacyclics, Server agree to end pan-HDAC inhibitor collaboration
Pharmacyclics and Servier announced that they have mutually and amicably ended their collaboration pertaining to the ex-U.S. development of Pharmacyclics' pan-HDAC inhibitor compounds involving abexinostat, thereby returning global development and commercialization rights to Pharmacyclics. A provisional patent application for abexinostat tosylate was filed with the U.S. Patent and Trademark Office in 2013 and, if issued, would extend patent protection until 2034. Pharmacyclics will evaluate the full opportunity that the compound may afford, and plans to provide an update on this program in mid 2015.
September 16, 2014
07:03 EDTPCYCPharmacyclics VA contract worth $6 per share, says William Blair
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use